Welcome to our dedicated page for Phathom Pharmaceuticals SEC filings (Ticker: PHAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Phathom is a biopharmaceutical company focused on gastrointestinal (GI) diseases, and its filings offer detailed information on VOQUEZNA (vonoprazan) commercialization, clinical programs, and corporate activity.
Through current reports on Form 8-K, Phathom reports material events such as quarterly and interim financial results, clinical trial milestones, leadership changes, and key scientific publications. For example, the company has used Form 8-K to announce financial results for specific quarters, publication of additional analyses from the Phase 3 pHalcon-NERD-301 trial in Non-Erosive GERD, and initiation of the Phase 2 pHalcon-EoE-201 study in eosinophilic esophagitis.
Filings also document capital markets transactions, including underwritten public offerings of common stock and pre-funded warrants, and provide details on the intended use of proceeds for working capital, commercialization, and research and development expenses. Disclosures about executive appointments and compensation arrangements, such as the appointment of a Chief Financial and Business Officer, are likewise reported in 8-K filings.
On Stock Titan, these SEC documents are complemented by AI-powered summaries that highlight the key points of lengthy filings, helping readers quickly understand topics such as operating performance, clinical trial updates, and corporate governance changes. Users can monitor real-time updates from EDGAR, review quarterly and annual reports when available, and examine current reports for insights into Phathom’s GI-focused business. This page serves as a central resource for investors and researchers who want to analyze PHAT’s official disclosures alongside concise AI-generated explanations.
Phathom Pharmaceuticals reported a Form 4 filing on June 28, 2025, disclosing stock option grants to Anne Marie Cook, the company's Chief Legal Officer & Corporate Secretary.
Key transaction details:
- Granted 210,000 stock options to purchase common stock
- Exercise price set at $9.47 per share
- Grant date: June 23, 2025
- Expiration date: June 22, 2035
The options follow a 4-year vesting schedule: 25% vests on June 23, 2026, with the remainder vesting in equal monthly installments over the following three years, contingent on continuous service. This grant appears to be part of the company's executive compensation program.
Anne Marie Cook has filed an initial Form 3 Statement of Beneficial Ownership following her appointment as Chief Legal Officer & Corporate Secretary at Phathom Pharmaceuticals (PHAT). The filing, dated June 28, 2025, discloses her beneficial ownership status as of June 23, 2025.
Key details of the filing:
- Cook currently owns no securities of Phathom Pharmaceuticals
- No derivative securities (options, warrants, etc.) are reported as beneficially owned
- The filing is made as an individual submission, not as part of a group
- Direct ownership form is indicated for the zero securities position
This Form 3 filing is a standard regulatory requirement for new officers, directors, and 10% shareholders under Section 16(a) of the Securities Exchange Act of 1934, establishing a baseline for future transaction reporting.